Navigation Links
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
Date:11/11/2013

ted with patient survival. 

"We believe that these additional findings from our Phase 2 trial support the in vivo mechanism of action of AGS-003," said Charles Nicolette, Argos' chief scientific officer and vice president of research and development, adding, "we also believe this is the first demonstration in a clinical trial that the magnitude of an adaptive immune response following immunotherapy correlates with prolonged survival."  

The Phase 2 clinical trial of AGS-003 in combination with sunitinib enrolled 21 intermediate and poor risk mRCC patients who had a time from diagnosis to initiation of systemic therapeutic treatment of less than one year. Fourteen of these patients were evaluable for immune responses, and median overall survival for these 14 patients was 39.5 months.

Earlier this year, Argos initiated a pivotal Phase 3 clinical trial for AGS-003 ("ADAPT"). The randomized, multicenter, open-label ADAPT clinical trial is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend OS versus standard therapy alone in newly diagnosed mRCC patients. Argos is using BTSVQ to analyze multi-color flow cytometry data in the ADAPT trial, which will enroll a total of 450 patients in approximately 130 global sites. 

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sampl
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... BURLINGTON, Mass. , July 30, 2014 /PRNewswire/ ... surveyed pharmacy and medical directors in ... key drivers of biosimilar market penetration will be ... care organizations (MCOs) and the expected lower cost ... strategies for biosimilars that meet their pricing expectations ...
(Date:7/30/2014)... -- The Chicago Bears are excited to announce the team,s ... an effort to raise awareness of skin cancer. Through ... me™ skin cancer screenings at a preseason fan event ... SPOT me™ is an educational campaign designed to inform the ... skin cancer, and encourages people to get screened by ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... 20 PreViser Corporation,( http://www.previser.com ), a Washington ... technology to the dental profession,announced today the finalization ... Ltd ( http://www.previser.co.uk ) of Birmingham, England to,market ... and the,Republic of Ireland., OHI Ltd is ...
... living computers by genetically altering bacteria. The findings of ... of Biological Engineering, demonstrate that computing in living cells ... applications including data storage and as a tool for ... from the biology and the mathematics departments of Davidson ...
... May 19 Amarin Corporation,plc (NASDAQ: AMRN ) ... quarter and full year ended December 31, 2007. For ... of $7.9 million, or,$0.72 per share, compared with a ... the fourth quarter of 2006. The increase in net ...
Cached Biology Technology:PreViser and Oral Health Innovations Ltd Form UK Partnership to Provide Oral Health Scoring and Risk Analysis 2Researchers bring new meaning to the term 'computer bug' 2Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 2Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 3Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 4Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 5Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 6Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 7Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 8Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 9
(Date:7/30/2014)... Progress in developing robust therapies for spinal cord injury ... has been slow. A great deal has been learned ... factors and the environmental factors that regulate axon growth, ... resulted in clinically available therapeutics. Prof. Lemmon and his ... therapeutic bottleneck has many root causes, but a consensus ...
(Date:7/30/2014)... the roughly 3,000 pieces is still in its infant ... will be of major significance. "Amazingly often, we are ... Fushun amber that we found in Baltic amber," explained ... Baltic amber comes from the Baltic Sea region, which ... finds are, e.g., the coastal regions of Mecklenburg, Poland ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... birth of eminent biologist today (Thursday) Charles Darwin a ... and protect Northern Ireland,s natural heritage. Queen,s University ... teamed up to form the Natural Heritage Research Partnership ... tendering. The project is being led by Quercus, ...
... Explorer SMOS satellite can take place between July and October ... Space are now making detailed preparations for the last crucial ... The Soil Moisture and Ocean Salinity (SMOS) satellite has been ... since May last year awaiting for a third stage of ...
... in German . The use of uranium ... that people may come into contact with it, and the ... However, radioactivity is not the only problem related to contact ... dangerous to human health. Researchers are still looking for simple, ...
Cached Biology News:Darwin anniversary heralds new conservation research era for Northern Ireland 2ESA's water mission on track for launch 2A pocketful of uranium 2
... Translation System is ideal for both radioactive ... Translation System: Provides five pre-mixed nucleotide ... Yields >10 8 cpm/g control ... to monitor the performance of the system ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
Biology Products: